Roche is a Swiss multinational healthcare company that is recognized for Research and Development in the 2022 Clinical Trials Arena Excellence Awards.
During this research period the company has been actively developing drugs for both rare and commonly occurring diseases. Some of these include diabetes, hepatitis, leukaemia, various oncological and age related conditions.
Go deeper with GlobalData
Roche’s Gazyvaro leukaemia drug performed well in and eventually completed its phase I/II trial. Some of the company’s other prospective drugs in early stage development include GalXC RNAi candidate, RG6346 and the oncological drug tiragolumab, which is being investigated in combination with Tecentriq (atezolizumab).
Promising drugs in late stage development include faricimab, which is intended to treat age-related macular degeneration, Tecentriq intended for the treatment of lung cancer, Venclexta/Venclyxto (venetoclax) for the treatment of leukaemia, Polivy (polatuzumab vedotin) for treating diffuse large B-cell lymphoma, Enspryng (satralizumab) for the treatment of neuromyelitis optica spectrum disorder and Hemlibra (emicizumab) for moderate or mild haemophilia A.
Company Profile
Roche is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.
In the market for 125 years Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas.
